DERMATA THERAPEUTICS INC (DRMA) Stock News

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

12 Health Care Stocks Moving In Friday's Pre-Market Session

Mentions: IRIX LXRX PTIX DBVT ...

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Mentions: DRCT LGMK AGX STSS ...

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Dermata to Present on BioPub on January 31, 2025

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

/PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of...

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: MRVL.CA CGTX ZVSA NRBO

Life Sciences Investor Forum Agenda Announced for November 14th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Mentions: ZVSA NRBO CGTX

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com –

DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dermata Therapeutics (NASDAQ:DRMA) just reported results for the second quarter...

7 F-Rated Growth Stocks to Avoid Like the Plague in August 2024

If your growth stocks have stopped growing then you may be holding on to F-rated growth stocks. It's time to sell.

Mentions: FCEL MULN NIO PLUG ...

DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024

DRMA stock results show that Dermata Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are a hot topic on Thursday morning and we have all of the latest news traders need to know about them!

Mentions: PBM TIVC BLMZ CERO ...